Immune therapy tested for rare, Tough-to-Treat cancers
NCT ID NCT03316573
Summary
This study is testing a drug called pembrolizumab for people with rare, aggressive cancers of the immune system (like certain lymphomas and histiocyte/dendritic cell sarcomas) that have come back or stopped responding to standard treatments. The drug aims to help the body's own immune system recognize and attack the cancer cells. The study is enrolling adults whose cancer has progressed despite prior therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Nebraska
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.